OTULIN deficiency in ORAS causes cell type-specific LUBAC degradation, dysregulated TNF signalling and cell death

Rune Busk Damgaard1,‡, Paul R Elliott1,‡, Kirby N Swatek1,‡, Eamonn R Maher2, Polina Stepensky3,4, Orly Elpeleg3,5, David Komander1,6,7,‡ & Yackov Berkun3,8,***

Abstract

The deubiquitinase OTULIN removes methionine-1 (M1)-linked polyubiquitin signals conjugated by the linear ubiquitin chain assembly complex (LUBAC) and is critical for preventing TNF-driven inflammation in OTULIN-related autoinflammatory syndrome (ORAS). Five ORAS patients have been reported, but how dysregulated M1-linked polyubiquitin signalling causes their symptoms is unclear. Here, we report a new case of ORAS in which an OTULIN-Gly281Arg mutation leads to reduced activity and stability in vitro and in cells. In contrast to OTULIN-deficient monocytes, in which TNF signalling and NF-κB activation are increased, loss of OTULIN in patient-derived fibroblasts leads to a reduction in LUBAC levels and an impaired response to TNF. Interestingly, both patient-derived fibroblasts and OTULIN-deficient monocytes are sensitised to certain types of TNF-induced death, and apoptotic cells are evident in ORAS patient skin lesions. Remarkably, haematopoietic stem cell transplantation leads to complete resolution of inflammatory symptoms, including fevers, panniculitis and diarrhoea. Therefore, haematopoietic cells are necessary for clinical manifestations of ORAS. Together, our data suggest that ORAS pathogenesis involves hyper-inflammation of immune cells and TNF-induced death of both leukocytes and non-haematopoietic cells.

Keywords cell death; deubiquitinases; inflammatory disease; TNF signalling; ubiquitin

Subject Categories Genetics, Gene Therapy & Genetic Disease; Immunology

DOI 10.15252/emmm.201809324 | Received 11 May 2018 | Revised 23 January 2019 | Accepted 29 January 2019 | Published online 25 January 2019

EMBO Mol Med (2019) 11: e9324

Introduction

Timely activation and resolution of the innate immune response is essential for tissue homeostasis and host defence, and dysregulation of this response may cause autoinflammation (Nathan & Ding, 2010). Autoinflammatory diseases are a heterogeneous group of disorders characterised by spontaneous development of episodic or chronic inflammation in the absence of inflammatory provocation. Causative mutations have been identified in more than 25 genes, most of which regulate cytokine signalling, e.g. interleukin-1 (IL-1), type 1 interferon, or tumour necrosis factor (TNF) signalling, or activation of nuclear factor-κB (NF-κB) transcription factors (Manthiram et al, 2017).

Key regulatory mechanisms in innate immune signalling rely on protein ubiquitination, which is a versatile post-translational modification that regulates virtually every aspect of cellular homeostasis (Komander & Rape, 2012). Ubiquitin (Ub) mediates most of its cellular functions through structurally and functionally distinct polyUb signals (Komander & Rape, 2012; Swatek & Komander, 2016). These polyUb chains can be linked via one of the seven Lys (K) residues in Ub (e.g. K48-linked chains) or via Ub Met1 (M1), forming M1-linked (also known as linear) chains (Swatek & Komander, 2016).

Ubiquitin chains regulate activation of NF-κB transcription factors to control inflammation and immunity (Bonizzi & Karin, 2004; Jiang & Chen, 2012; Etzioni et al, 2017). K48-linked chains mediate timed degradation of the inhibitor of κB (IκB) proteins while non-degradative chains, including K63- and M1-linked chains, serve as recruitment and activation platforms in signalling complexes formed after engagement of pattern recognition receptors (PRRs) and cytokine receptors, e.g. TNF receptor-1 (TNF-R1). Receptor stimulation, for example of TNF-R1, triggers assembly of
multi-protein receptor signalling complexes (RSCs) that include a host of E3 Ub ligases, including TNF receptor-associated factors (TRAFs), inhibitor of apoptosis proteins (IAPs) and the linear Ub chain assembly complex (LUBAC). These generate K63- and M1-linked Ub chains to facilitate the recruitment of the TGFβ-activated kinase 1 (TAK1) and IkB kinase (IKK) complexes, respectively (Jiang & Chen, 2012). K63 and M1 Ub linkages can occur in the same Ub polymers (Ememerich et al., 2013), facilitating TAK1 and IKK co-localisation and cross-activation (reviewed in Hrdinka & Gyrd-Hansen, 2017).

M1-linked Ub chains are conjugated by LUBAC, which consists of the catalytic subunit HOIP and the adaptors and co-activators HOIL-1 and SHARPIN (Kirisako et al., 2006; Gerlach et al., 2011; Ikeda et al., 2011; Tokunaga et al., 2011). LUBAC exclusively generates M1-linked Ub chains (Kirisako et al., 2006; Steglich et al., 2013) and is recruited in a Ub-dependent manner to many receptors of the immune system, including TNF-R1, IL-1 receptor (IL-1R), CD40, TLRs and NOD2, where it ubiquitinates a host of substrates, including RIPK1, RIPK2, MyD88, IRAKs and NEMO directly or on pre-existing chains (Hrdinka & Gyrd-Hansen, 2017).

Functionally, formation of RSCs and activation of the Ub- and kinase-dependent signalling cascades leads to activation of NF-κB transcription factors and pro-inflammatory transcriptional programmes (Jiang & Chen, 2012). However, for TNF-R1, it can also lead to cell death via formation of a TRADD-, FADD-, RIPK1/3- and caspase-8-containing death-inducing complex, complex-II (Fuchs & Steller, 2015; Kupka et al., 2016b). Recent research has shown that M1-linked Ub chains are key in determining the fate of a cell upon TNF stimulation. In the absence of LUBAC, TNF-mediated signalling is shifted from NF-κB activation towards induction of cell death via complex-II (Haas et al., 2009; Tokunaga et al., 2009; Gerlach et al., 2011; Ikeda et al., 2011; Peltzer et al., 2014, 2018). Mouse experiments have shown that the resulting TNF-induced cell death can be highly inflammatory as genetic ablation of LUBAC components leads to multi-organ inflammation (HogenEsch et al., 1993; Seymour et al., 1993; Stieglitz et al., 2013) and has severe splenomegaly and bilateral cataracts. Laboratory evaluation revealed elevated acute phase proteins, including C-reactive protein (CRP) and ferritin, elevated IL-6 and soluble IL-2 receptor (sIL-2R) in serum, severe anaemia, and leukocytosis with significant monocytes in the absence of any evidence of infection (Fig 1B and Appendix Clinical Description).

Deubiquitinases (DUBs) are proteases that cleave Ub modifications and functionally revert Ub signalling. Several DUBs, including A20 and CYLD, act as negative regulators of NF-κB signalling to balance activation and ensure resolution of inflammation (Harha & Dixit, 2012). OTULIN (OTU family deubiquitinase with linear Ub specificity, also known as FAM105B or Gumby) is the only DUB known to specifically cleave M1 linkages (Keusekotten et al., 2013; Rivkin et al., 2013). Several studies have shown that OTULIN binds directly to the LUBAC subunit HOIP (Elliott et al., 2014; Schaeffer et al., 2014; Takiuchi et al., 2014). In the absence of LUBAC, M1-linked Ub chains accumulate in cells and receptor signalling complexes, enhancing NF-κB activation in response to stimulation of TNF-R1 and NOD2 (Fiil et al., 2013; Keusekotten et al., 2013; Rivkin et al., 2013; Draber et al., 2015; Damgaard et al., 2016; Hrdinka et al., 2016; van Wijk et al., 2017). Interestingly, similar to LUBAC components, homozygous mutations in OTULIN were recently found to cause autoinflammation in humans (Damgaard et al., 2016; Zhou et al., 2016), showing that excessive M1-linked Ub signalling can be harmful. OTULIN-related autoinflammatory syndrome (ORAS) (also known as otulipenia or autoinflammation, panniculitis and dermatosis syndrome (AIPDS); OMIM ID: 617099) is a potentially fatal, TNF-driven autoinflammatory disease characterised by sterile systemic inflammation, recurrent high fevers, panniculitis, diarrhoea, arthritis and general failure to thrive (Damgaard et al., 2016; Zhou et al., 2016). Key features of ORAS are recapitulated in OTULIN-deficient mice (Damgaard et al., 2016). However, the cellular defects underlying the development of inflammation in ORAS remain unclear.

Here, we report a new case of ORAS identified by whole-exome sequencing of a patient with neonatal-onset, severe inflammatory symptoms. Primary fibroblast cultures from this patient reveal a surprising phenotype of deregulated M1-linked Ub signalling, whereby OTULIN loss coincides with LUBAC downregulation to prevent intrinsic NF-κB activation. In contrast, OTULIN-deficient myeloid cells are hyper-inflammatory and spontaneously activate NF-κB and secrete TNF. Both cell types, however, are sensitised to cell death in response to TNF. Importantly, we find that haematopoietic stem cell transplantation (HSCT) leads to complete resolution of all inflammatory symptoms associated with ORAS. This shows that haematopoietic cells are crucial for the clinical manifestation of ORAS and indicates HSCT could be a curative treatment for the disease.

**Results**

**Inflammatory symptoms in a patient with homozygous OTULIN mutations**

A female patient of Arab origin (patient III.2), the second of three children born to first-degree related parents (her grandfathers are identical twins; Fig 1A), developed severe inflammatory symptoms shortly after birth. From the age of 3 days, she developed severe idiopathic, systemic inflammation and had recurrent episodes of high fever in combination with widespread panniculitis (Fig 1B and Appendix Clinical Description). At the age of 7 months, her symptoms included high fevers, diarrhoea and panniculitis, and she was cachectic, weighing 3.4 kg (<3rd percentile; WHO Multicentre Growth Reference Study Group, 2006) and had severe splenomegaly and bilateral cataracts. Laboratory evaluation revealed elevated acute phase proteins, including C-reactive protein (CRP) and ferritin, elevated IL-6 and soluble IL-2 receptor (sIL-2R) in serum, severe anaemia, and leukocytosis with significant monocytes in the absence of any evidence of infection (Fig 1B and Appendix Clinical Description).

The consanguineous relations in the family (Fig 1A) indicated that patient III.2 suffered from an autosomal recessive disorder. Genetic testing excluded Mediterranean fever and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome caused by mutations in MEFV and PSMB8, respectively. Whole-exome sequencing (WES) was performed to investigate patient III.2’s underlying genetic defect. Filtering out all common and heterozygous variants, WES revealed a single, homozygous G-to-A substitution in OTULIN, c.841G>A; p.Gly281Arg, in patient III.2 (Figs 1A and C and...
Appendix Table S1). The parents of patient III.2 (II.1 and II.2) and her sister (III.1) were heterozygous for the substitution, whereas her brother (III.3) did not carry the mutation (Figs 1A and C). WES revealed no other homozygous or previously annotated pathogenic variants likely to cause the disease phenotype (Appendix Table S1).

Mutations in OTULIN have recently been described to cause ORAS, an autosomal recessive autoimmune inflammatory disease (Damgaard et al., 2016; Zhou et al., 2016). Patient III.2’s symptoms, as well as the course of disease and effect of treatments (see below, Appendix Clinical Description), resembled those of other ORAS patients (Damgaard et al., 2016; Zhou et al., 2016). Hence, patient III.2 was diagnosed with ORAS.

Mutation of Gly281 to Arg reduces OTULIN’s activity towards M1-linked Ub by unfolding the substrate-binding site

To date, three different mutations in OTULIN have been reported in families with patients affected by ORAS. In one family, a single nucleotide deletion introduces a premature stop codon, Gly174Aspfs*2, leading to deletion of roughly two-thirds of the catalytic OTU domain (Zhou et al., 2016) and thus likely a complete loss of function although the N-terminal fragment may be present in cells. Hypomorphic Leu272Pro and Tyr244Cys missense mutations were identified in two other families (Damgaard et al., 2016; Zhou et al., 2016). Leu272 is located in the Ub-binding pocket in the OTU domain and the mutation to Pro impairs M1-linked diUb binding, catalytic efficiency and stability of OTULIN (Damgaard et al., 2016). Tyr244 is not found or predicted to make any contacts to Ub or be involved in catalysis (Keusekotten et al., 2013), and the main effect of the Tyr244Cys mutation might be reduced protein stability (Zhou et al., 2016).

Similar to Leu272 and Tyr244, Gly281 is also located in the OTU domain (Keusekotten et al., 2013). Gly281 is evolutionarily conserved and located in a loop between helices α11 and α12 (Fig EV1A; Keusekotten et al., 2013). Together with His282 and Thr283, Gly281 forms part of the Ub-binding site and makes direct contacts to the proximal Ub of M1-linked diUb bound across the active site (Figs 2A, centre panel and EV1A; Keusekotten et al., 2013). While Gly281 is in an important region, the effect of the mutation to Arg is difficult to predict. To understand the pathogenicity of the Gly281Arg mutation on OTULIN, we crystallised OTULIN’s catalytic domain (OTULINcat, aa 80–352) containing the Gly281Arg ORAS mutation (OTULINcatG281R) and determined its structure to 1.8 Å resolution (Figs 2A and Appendix Table S2). Overall, the structure showed that OTULINcatG281R adopted an OTU fold similar to OTULINcatWT (Keusekotten et al., 2013) without any major perturbations (Fig 2A). However, comparing the structure of OTULINcatG281R with the previously solved structure of OTULINcat in complex with M1-linked diUb (Keusekotten et al., 2013) showed that the Gly281Arg mutation partly unfolds the substrate-binding site (Fig 2A, right panel). The introduced Arg side chain can no longer fit into the narrow pocket between helices α3 and α9 thereby flipping the Gly281-containing loop out of its normal binding groove (Figs 2A and B; Keusekotten et al., 2013). In the mutant protein, the loop has increased flexibility, as represented by the high crystallographic B-factor distribution across the loop compared to other regions within the OTU domain (Fig EV1B) and also evidenced by lack of interpretable electron density for the side chains of Val280, mutated Arg281 and His282 (Fig EV1C). The new conformation of the Gly281-containing loop indicated that His282 and Thr283 would clash with M1-linked diUb at the binding site and prevent substrate binding (Fig 2B).

We probed the binding of M1-linked diUb to catalytically inactive OTULINC129A or OTULINC129A/G281R. As indicated from the structure, the Gly281Arg mutation strongly reduced binding of M1-linked diUb to OTULIN and the dissociation constant (Kd) of OTULINC129A/G281R and M1-linked diUb was 9.3 μM compared with 85 nM in OTULINC129A (Fig 2C).

The reduced substrate binding by OTULING281R was also reflected in catalytic activity. OTULING281R was ~20-200 times less
active towards M1-linked tetraUb compared with OTULIN WT (Fig 2D). At a 5 nM concentration, OTULIN WT cleaved ~50% of the M1-linked tetraUb intro tri-, di- and mono-Ub within 5 min and all tetraUb was processed at 15 min. In contrast, between 100 nM and 1 µM of OTULIN G281R was needed to achieve the same catalytic efficiency (Fig 2D).
In addition to reduced Ub binding and activity, the Gly281Arg mutation caused a considerable intrinsic destabilisation of OTULIN. Monitoring protein unfolding over a thermal gradient, we observed that the melting temperature \( T_m \) was reduced from 56.5°C for OTULIN\(_{WT} \) to 50.9°C for OTULIN\(_{G281R} \) (Figs 2E and EV1D). This intrinsic loss of stability indicates a defect in folding of the mutant. Such defects can be exacerbated in cells where partially damaged or unfolded proteins trigger protein quality control mechanisms, including protein degradation.

**M1-linked Ub accumulation and destabilisation of OTULIN\(_{G281R} \) and LUBAC in patient fibroblasts**

The cellular defects underlying the development of inflammation in ORAS are unclear. To study how OTULIN mutations impact on non-haematopoietic cells and how these cells may contribute to the clinical aspects of ORAS, e.g. panniculitis, we established a primary dermal fibroblast culture from patient III.2. Surprisingly, immunohistochemical analysis of tissue sections of ORAS biopsies revealed an absence of LUBAC expression in patient dermal fibroblasts (Fig 2A). The cellular composition of Ub chain types, we used a non-selective tandem Ub-binding entity (TUBE; Hjerpe et al., 2009) to purify polyUb chains from cells in a non-linkage-selective manner (Fig 3C). The polyUb chains purified by the TUBE were analysed by absolute quantification (AQUA) tandem mass spectrometry (MS/MS; Kirkpatrick et al., 2006; Fig 3C). K6, K48 and K63 linkages combined comprised ~80–85% of the cellular polyUb chains and did not change, while K27, K29 and K33 linkages were undetectable or unquantifiable in the OTULIN\(_{G281R} \) and control fibroblasts (Figs 3D and EV2F and G). Curiously, we noted a reduction in K11 linkages from ~19% in healthy control fibroblasts to ~10% in OTULIN\(_{G281R} \) cells (Figs 3D and EV2F and G). Immunoblotting showed no apparent overall differences in the total levels of Ub conjugates or free Ub in whole-cell lysates between the patient fibroblasts and healthy control cells (Fig 3E).

Strikingly, despite the reduction in LUBAC levels, the AQUA-MS/MS analysis revealed a considerable increase in M1-linked Ub chains from ~0.5% in healthy controls to ~3.5% in OTULIN\(_{G281R} \) fibroblasts (Figs 3D and EV2F and G). This implies that the remaining LUBAC is still active and may function unantagonised. The increase in cellular M1 Ub levels, however, was hardly detectable by immunoblotting, and only a very faint increase in the high molecular weight smear was observed in the OTULIN\(_{G281R} \) fibroblasts (Fig 3E). This indicates that the increase in M1 linkages might be relatively low compared to the levels observed in OTULIN-deficient cells that retain LUBAC expression (Draber et al., 2015; Damgaard et al., 2016; van Wijk et al., 2017). Consistently, OTULIN\(_{G281R} \) fibroblasts exhibited no appreciable signs of spontaneous p65/RelA phosphorylation or IκBα degradation (Fig 3F and G). This suggests that, in the absence of OTULIN, LUBAC is down-regulated via proteasomal degradation in the patient fibroblasts, potentially to reduce the levels of M1-linked Ub and prevent intrinsic activation of NF-κB signalling.

**Signalling from the TNF-RSC is impaired in OTULIN\(_{G281R} \) fibroblasts**

Decreased OTULIN function increases M1-linked Ub conjugation and NF-κB activation in response to TNF stimulation in LUBAC-proficient cells (Fiil et al., 2013; Keusekotten et al., 2013; Damgaard et al., 2016; Hrdinka et al., 2016). Yet, it is unknown how ORAS cells with concomitant reduction of HOIP and SHARPIN levels respond to TNF-R1 engagement. We treated the primary OTULIN\(_{G281R} \) patient fibroblasts with TNF and analysed NF-κB and MAP kinase activation by immunoblotting. Interestingly, in contrast to other OTULIN-deficient cells or cells with RNAi-mediated knock-down of OTULIN (Fiil et al., 2013; Keusekotten et al., 2013; Damgaard et al., 2016; Hrdinka et al., 2016), TNF signalling was decreased in OTULIN\(_{G281R} \) fibroblasts, although not completely abrogated (Fig 4A–C), similar to the response of LUBAC-deficient cells (Haas et al., 2009; Gerlach et al., 2011; Ikeda et al., 2011; Tokunaga et al., 2011; Peltzer et al., 2014). Stimulation with TNF led to decreased phosphorylation and degradation of IκBα as well as reduced phosphorylation of p65/RelA compared with healthy controls (Fig 4A and C). Similarly, phosphorylation and activation of the MAP kinases p38 and JNK was impaired in the OTULIN\(_{G281R} \) fibroblasts (Fig 4B). This correlated with a substantial reduction in IL-8 secretion from the patient cells in response to TNF (Fig 4D), showing that reduced NF-κB and MAP kinase signalling leads to functional impairment of innate immune signalling in the ORAS fibroblasts in response to TNF.

After stimulation of TNF-R1, LUBAC translocates to the TNF-RSC and conjugates M1-linked Ub chains to multiple components of the complex (Gerlach et al., 2011; Draber et al., 2015). We immunoprecipitated the native TNF-RF after stimulation with TNF, and indeed
However, in the OTULING281R fibroblasts, recruitment of LUBAC to TNF-R1 from healthy control fibroblasts (Fig 4E).

all three LUBAC components, HOIP, SHARPIN and HOIL-1, together with high molecular weight M1-linked Ub conjugates, co-precipitated with TNF-R1 from healthy control fibroblasts (Fig 4E). However, in the OTULING281R fibroblasts, recruitment of LUBAC to TNF-R1 was strongly reduced and hardly detectable (Fig 4E). Interestingly, also HOIL-1, which remains relatively stable in the patient fibroblasts, could hardly be detected at TNF-RSC, further confirming that HOIL-1 and SHARPIN are recruited in a HOIP-dependent manner (Draber et al, 2015). Consistently, the amount of M1-linked Ub conjugates, but not total Ub conjugates, at the TNF-RSC was drastically reduced in the patient cells (Fig 4E). Collectively, this suggests that the primary effect of OTULIN loss in the patient fibroblasts, namely the degradation of LUBAC components to prevent intrinsic signalling and autoactivation, results in a secondary effect: the failure to mount a sufficient LUBAC-dependent response to TNF stimulation.

NF-κB activation and TNF secretion in human OTULIN-deficient monocytes

Conditional deletion of OTULIN in myeloid cells recapitulates many aspects of ORAS in mice (Damgaard et al, 2016). This is associated with increased NF-κB activation and spontaneous TNF secretion from OTULIN-deficient BMDMs, which, in contrast to T cells, B cells, MEFs and ORAS fibroblasts, retain normal LUBAC levels after loss of OTULIN (Damgaard et al, 2016; Figs 3A and EV2C). Yet, how human myeloid cells react to loss of OTULIN is unclear. To assess this, we analysed NF-κB activation and TNF

---

**Figure 3.** LUBAC degradation and accumulation of M1-linked Ub in OTULING281R fibroblasts.

A Immunoblot analysis of whole-cell lysates from untreated primary healthy control and patient fibroblasts. Data are representative of three independent experiments.

B Immunoblot analysis of whole-cell lysates from primary healthy control and patient fibroblasts either left untreated or treated with the proteasome inhibitor MG132 (20 μM) for 24 h. Data are representative of two independent experiments.

C Schematic representation of the AQUA-MS/MS-based proteomics approach for quantification of cellular Ub linkage composition.

D Ub linkage composition

E, F Immunoblot analysis of whole-cell lysates from untreated primary healthy control or patient fibroblasts. Data are representative of three independent experiments.

G Immunoblot (left) and densitometry (right) analysis of IκBα levels in primary healthy control and patient fibroblasts treated with cycloheximide (CHX) (50 μg/ml) as indicated. Data are representative of three independent experiments.

Source data are available online for this figure.

---

---
secretion in human THP-1 monocytes with stable, short-hairpin RNA (shRNA)-mediated knock-down of OTULIN (shOTULIN cells) compared with cells expressing a non-targeting shRNA (shControl cell) (Hrdinka et al., 2016). The shOTULIN THP-1 cells showed substantial reduction in cellular OTULIN levels, although some OTULIN remained (Fig 5A). Similar to OTULIN-deficient murine BMDMs, LUBAC remained stable in shOTULIN cells and the levels of HOIP, HOIL-1 and SHARPIN were indistinguishable from those of shControl cells (Fig 5A). Importantly, OTULIN deficiency in THP-1 monocytes led to spontaneous phosphorylation of p65/RelA (Fig 5A) and drastically increased turnover of IκBα after TNF stimulation in the shOTULIN cells compared with shControls (Figs 5D and E).

This shows that also human OTULIN-deficient myeloid cells have a TNF-associated hyper-inflammatory phenotype and indicates that myeloid cells may be fundamentally different from fibroblasts in their response to loss or reduction of OTULIN function.

**OTULIN deficiency sensitises fibroblasts and monocytes to TNF-induced cell death**

Disruption of TNF-induced NF-κB activation in various tissues and cell types can result in inflammation due to increased cell death (Pasparakis, 2009). The autoinflammatory conditions caused by LUBAC deficiency are examples of this. SHARPIN-deficient cpdm (chronic proliferative dermatitis) mice (HogenEsch et al., 1993; Seymour et al., 2007; Gerlach et al., 2011; Ikeda et al., 2011) and patients with mutations in HOIP or HOIL-1 (Boisson et al., 2012, 2015, 2015) develop severe autoinflammatory syndromes. LUBAC destabilisation caused by these genetic alterations impairs TNF signalling and NF-κB activation (Gerlach et al., 2011; Ikeda et al., 2011; Ikeda et al., 2011).
2011; Tokunaga et al., 2011; Boisson et al., 2012, 2015), leading to TNF-R1-dependent induction of (mainly) TRADD-, FADD- and caspase-8-dependent apoptosis (Gerlach et al., 2011; Ikeda et al., 2011; Pelzer et al., 2014, 2018), which is the main driver of inflammation (Kumari et al., 2014; Rickard et al., 2014). Additionally, knock-in mice expressing catalytically inactive OTULIN C129A die mid-gestation (~E10.5) due to aberrant cell death (Heger et al., 2018), similar to HOIP- or HOIL-1-deficient mice (Pelzer et al., 2014, 2018). We tested whether OTULIN G281R ORAS fibroblasts were sensitised to TNF-induced cell death. Interestingly, we found that OTULIN G281R fibroblasts, despite their reduction in LUBAC levels, were not sensitive to cell death induced by TNF (Fig 6A) or a range of other stimuli (Fig EV3A). This is in contrast to LUBAC-deficient cells (Gerlach et al., 2011; Ikeda et al., 2011; Pelzer et al., 2014, 2018) or cells expressing inactive OTULIN C129A (Heger et al., 2018), which are all sensitive to cell death induced by TNF alone. We found, however, that the OTULIN G281R fibroblasts were sensitive to cell death induced by treatment with TNF in combination with the protein synthesis inhibitor cycloheximide (CHX; Fig 6A), suggesting that under certain stress conditions the patient fibroblasts are sensitised to TNF-induced cell death.

TNF-induced cell death may occur either via caspase-dependent apoptosis or RIPK1 kinase-dependent necroptosis (Fuchs & Steller, 2015). Treatment of the OTULIN G281R fibroblasts with the general caspase inhibitor Q-VD-OPh or the RIPK1 kinase inhibitor necrostatin-1 (Nec-1) showed that caspase inhibition rescued the majority of the TNF-induced cell death in LUBAC-deficient cells (Fig 6B). Nec-1 treatment alone only conferred mild protection against cell death, but treatment of ORAS fibroblasts with a combination of Q-VD-OPh and Nec-1 led to an almost complete rescue (Fig 6B). This shows that the OTULIN G281R fibroblasts likely die by apoptosis and to a lesser extent by necroptosis, consistent with the mode of TNF-induced cell death observed in LUBAC-deficient cells in culture and in SHARPIN-deficient cpdm mice (Gerlach et al., 2011; Ikeda et al., 2011; Berger et al., 2014; Kumari et al., 2014; Rickard et al., 2014).

Interestingly, despite their normal LUBAC levels, the shOTULIN ORAS fibroblasts were also sensitised to TNF+CHX-induced cell death,
but not to cell death by TNF alone (Figs 6C and EV3B), similar to the OTULIN G281R fibroblasts. The cell death in shOTULIN cells could completely be prevented by treatment with Q-VD-Oph, and Nec-1 treatment had no significant effect, neither alone nor in combination with caspase inhibition (Fig 6D). This is consistent with a recent report showing that LUBAC, in addition to its pro-survival role at TNF-R1, also contributes to TNF-induced apoptosis by inducing cFLIP degradation (Tang et al., 2018).

Inactivation of OTULIN by expression of OTULIN C129A in adult mice has recently been reported to cause systemic inflammation, which can be prevented by combined ablation of cell death pathways by deletion of caspase-8, RIPK3 and RIPK1 (Heger et al., 2018). Together with the increased cell death we observe in vitro, this suggests that cell death may contribute to ORAS pathogenesis. We analysed skin biopsies from ORAS patient III.2, taken at an inflammatory flare, and healthy control subjects for markers of cell death. Skin from the ORAS patient showed evidence of prominent inflammation with diffuse neutrophil infiltration, particularly around adipocytes, in the dermis and subcutaneous tissues, consistent with panniculitis (Fig 6E and Appendix Clinical Description).
This inflammation correlated with the presence of cleaved caspase-3-positive and TUNEL-positive cells in the dermis and subcutaneous tissues (Fig 6E), showing that cell death occurs in vivo during ORAS inflammation. Intriguingly, cleaved caspase-3-positive cells appeared to be mainly mesenchymal cells, including fibroblasts (Fig 6E, centre panels, arrowheads), whereas TUNEL-positive cells appeared to be mainly infiltrating leukocytes (Fig 6E, bottom panels).

These data show that cell death (including apoptosis) occurs in ORAS and that it may contribute to the TNF-driven pathogenesis of the disease.

**Haematopoietic stem cell transplantation ameliorates ORAS**

Previously, we have shown that deletion of OTULIN in all haematopoietic cell types in mice, or in myeloid cells alone, is sufficient to recapitulate key features of ORAS (Damgaard et al., 2016). But whether haematopoietic cells are necessary or sufficient to drive ORAS in humans is unknown. Importantly, we could use the case of ORAS in patient III.2 to address this retrospectively. As outlined, patient III.2 developed severe inflammatory symptoms within the first months of her life and she had a poor response to conventional anti-inflammatory treatment (Appendix Clinical Description). From the age of 8 months, she was treated with prednisone and colchicine, to which she only had a partial response (Fig 7A), similar to previous reports from ORAS patients (Damgaard et al., 2016; Zhou et al., 2016). At the age of 11 months, the recombinant IL-1 receptor antagonist anakinra was added to the treatment regimen without any improvement of her symptoms. Because of this poor response to treatment and the impaired pre-transplant performance status of the patient, HSCT was performed at the age of 17 months (Fig 7A) with reduced intensity fludarabine-based conditioning that included fludarabine (30 mg/m²/day for 6 days), busulphan (3.2 mg/kg/day for 4 days) and thiopeta (10 mg/kg/day for 1 day) together with anti-thymocyte globulin (ATG) (10 mg/kg). The donor was the patient’s HLA-matched father. The course of transplantation was uneventful, and 100% donor chimerism was achieved 17 days after HSCT (Fig 7B and Appendix Clinical Description). Remarkably, HSCT resulted in complete resolution of all inflammatory symptoms, including panniculitis, arthritis and diarrhoea, and the patient experienced complete clinical remission (Fig 7A and Appendix Clinical Description). As we and others have found signalling and cell death defects in OTULIN-deficient non-haematopoietic cells (Figs 3 and 4; Heger et al., 2018), complete remission after HSCT strikingly shows that OTULIN deficiency in haematopoietic cells is necessary for clinical manifestation of ORAS including the organ-specific symptoms panniculitis and diarrhoea (Fig 7D).

Nine months after HSCT, at the age of 26 months, patient III.2 relapsed with fever, panniculitis and arthritis, albeit with less severe symptoms than before the transplantation (Fig 7A and C, and Appendix Clinical Description). The relapse correlated with a progressive decrease in bone marrow chimerism and regrowth of patient III.2’s haematopoietic cells (Fig 7B). In mice, bone marrow chimerism with 50% OTULIN-deficient cells is sufficient to cause severe systemic ORAS-like inflammation (Damgaard et al., 2016), indicating that the decrease in chimerism observed in patient III.2 (Fig 7B) is sufficient to cause the relapse.

After the relapse, treatment with prednisone was resumed until the age of 29 months where patient III.2 started treatment with the TNF-blocking agent etanercept (soluble TNF receptor fusion protein; 0.4 mg/kg, twice weekly; Fig 7A and Appendix Clinical Description). This led to immediate and complete resolution of her inflammatory symptoms, and corticosteroid treatment was discontinued. Now, at age ~12 years, patient III.2 is treated with low dose etanercept (0.8 mg/kg) every 10 days and she remains asymptomatic as long as administration is regular (Fig 7C and Appendix Clinical Description).

Collectively, these data show that haematopoietic cells are required for clinical manifestation of ORAS and confirm that TNF is the driver cytokine for all inflammatory aspects of the disease (Damgaard et al., 2016), adding ORAS to the growing list of TNF-related pathologies (Kalliolias & Ivashkiv, 2016; Manthiram et al., 2017). Intriguingly, the dependence on OTULIN-deficient haematopoietic cells for ORAS implies that myeloid cells are the main drivers of the TNF-mediated inflammation (Figs 5 and 7D), as OTULIN deficiency in B or T cells alone in mice does not produce any inflammatory phenotypes (Damgaard et al., 2016). Moreover, it indicates that cell death in ORAS might be a key contributing and amplifying result of TNF-mediated inflammation (Figs 6E and 7D).

**Discussion**

Here, we report a new case of ORAS caused by homozygous hypomorphic c.841G>A; p.Gly281Arg mutations in a patient from a consanguineous family. To date, only three families (five patients) with OTULIN mutations and ORAS manifestations had been reported (Damgaard et al., 2016; Zhou et al., 2016) and numerous mouse studies (reviewed in Hrdinka & Gyrd-Hansen, 2017). Interestingly, the clinical result of mutations in HOIL-1 or HOIP (i.e. reduced M1-linked Ub conjugation) or in OTULIN (i.e. reduced M1-linked Ub hydrolysis) is the same: inflammation. Clinically, HOIL-1 and OTULIN deficiency manifests similarly with neonatal-onset systemic inflammation, recurrent fevers and failure to thrive (Boisson et al., 2012; Damgaard et al., 2016; Zhou et al., 2016). However, some important differences between these diseases exist. HOIL-1 deficiency is associated with severe primary immunodeficiency, cardiomyopathy and muscle weakness (Boisson et al., 2012; Nilsson et al., 2013; Wang et al., 2013), of which there is no evidence in ORAS patients (Damgaard et al., 2016; Zhou et al., 2016). In addition, TNF blockade is highly effective in all ORAS patients reported. Standard immunosuppression (e.g. corticosteroids) is, on the other hand, generally ineffective (Damgaard et al., 2016; Zhou et al., 2016). In contrast, corticosteroid treatment is generally effective in HOIL-1 deficiency whereas anti-TNF treatment in these patients is not (Boisson et al., 2012). This suggests that the underlying defects causing these syndromes, while overlapping, may be different.

OTULIN-related autoinflammatory syndrome patients respond poorly to standard anti-inflammatory and immunosuppressive
treatments (Damgaard et al., 2016; Zhou et al., 2016), but their inflammatory symptoms can be alleviated by neutralisation of TNF (Damgaard et al., 2016; Zhou et al., 2016). These treatments, however, have to be regular (and likely lifelong) as omission or delay in administration can cause inflammation to flare-up (Fig 7C and Appendix Clinical Description). Currently, there is no cure for ORAS.
We provide here the first report of the outcome of HSCT for ORAS. Remarkably, HSCT led to complete remission of the patient’s severe ORAS symptoms, including panniculitis, arthritis and diarrhoea, showing that haematopoietic cells are crucial for manifestation of the disease. The patient’s unfortunate relapse appears to be due to regrowth of her haematopoietic cells (Fig 7B). The decreased donor chimerism is most likely a consequence of the reduced intensity pre-transplantation conditioning, which may have enabled proliferation of residual haematopoietic stem cells in the patient, leading to a drop in donor chimerism and a relapse of inflammatory symptoms. We therefore suggest the use of more intense, fully myeloablative conditioning regimes as preparation for HSCT if such regimes can be tolerated by the recipients. Despite the patient’s relapse, this case supports further studies into HSCT as a potential treatment to ameliorate ORAS.

The Gly281Arg mutation identified in this study has a drastic impact on OTULIN. Not only does it reduce binding of and catalytic activity towards M1-linked Ub chains, but it also destabilises the protein such that OTULING281R is hardly detectable in the absence of proteasome inhibitor in patient fibroblasts. Destabilisation of OTULIN by ORAS mutations has been described for two other point mutations, Leu272Pro and Tyr244Cys, as well as the premature stop mutant Gly174Aspfs*2 (Damgaard et al., 2016; Zhou et al., 2016). The combination of reduced catalytic activity and very low protein levels of OTULING281R in cells indicates that the mutation might cause close to a complete loss of OTULIN function in vivo. The effect of the Gly281Arg mutation on OTULIN is similar in mechanism to the Leu272Pro mutation identified in a different ORAS family (Damgaard et al., 2016; Zhou et al., 2016). Collectively, this strongly suggests that ORAS is a disease of loss or significant reduction of OTULIN activity and expression.

In cells, we observed a considerable increase in M1 Ub linkages in the OTULING281R patient fibroblasts, despite the drastically reduced HOIP and SHARPIN levels. At steady state, the cellular levels of M1-linked Ub are very low (Figs 3D and EV2F) (Fiil et al., 2013; Keusekotten et al., 2013; Draber et al., 2015), yet they accumulate transiently in receptor complexes to facilitate signalling (Fig 4E) (Gerlach et al., 2011; Emmerich et al., 2013; Fiil et al., 2013; Keusekotten et al., 2013; Peltzer et al., 2014; Rickard et al., 2014; Draber et al., 2015; Hrdinka et al., 2016; Kupka et al., 2016a). This suggests that M1-linked Ub is a potent and highly regulated signal that is strictly controlled in cells to prevent intrinsic activation or dysregulation of signalling. In the OTULING281R fibroblasts, we observed a chronic and global accumulation of M1-linked Ub chains (Figs 3D and EV2F and G) together with a striking concomitant reduction in LUBAC levels and no evidence of spontaneous NF-κB activation (Figs 3A, F and G). This suggests that in certain cell types, e.g. T and B cells (Damgaard et al., 2016) and fibroblasts (Figs 3A and EV2C), the potentially uncontrolled M1-linked Ub accumulation in the absence of OTULIN may function as a “stress” signal that somehow feeds back and reduces LUBAC activity by downregulating the level of this complex via the proteasome, thereby maintaining homeostasis by preventing or reducing intrinsic activation of inflammatory signalling. However, downregulation of LUBAC also means that these cells cannot respond appropriately to external signals, including TNF, which may in turn contribute to ORAS pathogenesis (Fig 7D, see below).

Different cell types respond differently to loss of OTULIN. In murine models, LUBAC is stable in OTULIN-deficient myeloid cells, but not in B and T cells where HOIP and SHARPIN levels are reduced (Damgaard et al., 2016). Reduction in LUBAC levels, primarily in HOIP and SHARPIN, has also been reported in fibroblasts from three different ORAS patients (Zhou et al., 2016). Similarly, we observe here that HOIP and SHARPIN levels are reduced in OTULING281R fibroblasts while LUBAC remains stable in OTULIN-deficient THP-1 monocytes. This striking cell type-specific effect on LUBAC suggests that the phenotype of different cell types upon loss of OTULIN may depend on their LUBAC status. LUBAC exists, at least, as a trimeric HOIP-HOIL-1-SHARPIN complex (Gerlach et al., 2011; Ikeda et al., 2011; Tokunaga et al., 2011), but the stoichiometry of components and whether it varies between cell types is unknown. Specific subpopulations of LUBAC, e.g. dimeric HOIP-HOIL-1 or HOIP-SHARPIN complexes or complexes stably associated with other factors such as DUBs, remain a topic of active investigation. Recently, it was reported that OTULIN and CYLD, via its adaptor SPATA2, utilise the same mechanism to interact with HOIP, thereby forming mutually exclusive complexes (Draher et al., 2015; Elliott et al., 2016). This suggests that distinct pools of LUBAC-DUB complexes may exist (Hrdinka & Gyrd-Hansen, 2017). The apparently specific downregulation of HOIP and SHARPIN in ORAS patient fibroblasts (Fig 3A; Zhou et al., 2016) and in T and B cells (Damgaard et al., 2016) might suggest that OTULIN could be a part of and/or regulate a distinct HOIP-SHARPIN complex. However, this needs further investigation. Our data suggest that careful assessment of steady state levels of OTULIN and LUBAC, and possibly CYLD, is necessary for appropriate interpretation of experiments involving OTULIN, LUBAC and M1-linked Ub signalling.

OTULING281R fibroblasts are functionally LUBAC-deficient after TNF stimulation. LUBAC recruitment and M1-linked Ub conjugation at the TNF-RSC are reduced, accompanied by impaired TNF signalling, decreased IL-8 secretion and sensitisation to TNF-induced cell death in the presence of CHX (Fig 4). Interestingly, OTULIN-deficient THP-1 cells, which are hyper-inflammatory and hyper-signal in response to TNF (Fig 6), are also sensitive to this form of cell death, despite their normal levels of LUBAC. These observations suggest that ORAS may not only be caused by TNF-induced hyper-signalling and cytokine secretion (Damgaard et al., 2016), but that ORAS pathogenesis may also involve cell death (Fig 7D). Our analysis of cell death in biopsies from ORAS patient III.2 supports this notion and provides clear evidence of apoptosis in the skin of this patient at the time of an inflammatory flare. This bears resemblance to the dermatitis phenotypes in LUBAC-deficient mice and the cell death observed in LUBAC-deficient cells (Kumari et al., 2014; Peltzer et al., 2014, 2018; Rickard et al., 2014; Taraborrelli et al., 2018). However, in contrast to LUBAC deficiency where cells are sensitised to cell death induced by TNF alone, OTULIN-deficient cells need additional perturbation (i.e. CHX) before they become sensitive to TNF-induced death. This could suggest that cell death of OTULIN-deficient cells may be a secondary effect of a “stressed” environment, such as an inflamed tissue. The dermatitis in SHARPIN-deficient cpdm mice is caused by cell or tissue intrinsic defects leading to TNF-induced cell death of keratinocytes (Kumari et al., 2014; Rickard et al., 2014) and it is not mediated by immune cells as allogeneic BM or splenocyte transplantations fail to transfer the disease to WT mice (Hogen-Esch et al., 1993; Rickard et al., 2014). In contrast, OTULIN deficiency in haematopoietic cells is necessary for manifestation of skin inflammation/panniculitis in ORAS patients as demonstrated...
here by HSCT (Fig 7A–C and Appendix Clinical Description). Yet, mouse models indicate that OTULIN deficiency in haematopoietic cells is not sufficient for development of the full spectrum of ORAS symptoms. Mice with genetic ablation of OTULIN either in all haematopoietic cell types or specifically in myeloid cells develop systemic ORAS-like inflammation, but the organ-specific symptoms that are hallmarks of the human disease (panniculitis, diarrhoea and arthritis) do not manifest spontaneously in these models (Damgaard et al., 2016). The full clinical disease in ORAS may therefore be a “compound” phenotype where hyper-inflammatory, TNF-secreting haematopoietic (myeloid) cells cause TNF-induced inflammation and cell death of both non-haematopoietic cells with LUBAC downregulation, e.g. dermal fibroblasts, and haematopoietic cells (Fig 7D), thereby giving rise the organ-specific hallmark symptoms panniculitis, diarrhoea and arthritis.

Together, these clinical and experimental data expand our understanding of the cellular mechanisms leading to ORAS development and indicate HSCT as a new potential treatment to ameliorate ORAS.

Materials and Methods

Whole-exome analysis

Exonic sequences from a DNA sample from patient III.2 were enriched using SureSelect Human All Exon 50 Mb V.5 Kit (Agilent Technologies, Santa Clara, CA) and sequenced on an Illumina HiSeq2500 (Illumina, San Diego, CA) with 100-bp paired-end reads. Data were analysed on the DNAnexus platform (DNAnexus, Inc., Mountain View, CA) using default parameters with the human genome assembly hg19 (GRCh37) as reference. For further details, see Appendix Supplementary Methods.

Expression and purification of recombinant proteins

OTULIN and TUBE proteins were purified from E. coli as described in (Elliott et al., 2014) and (Hrdinka et al., 2016), respectively. For further details, see Appendix Supplementary Methods.

Qualitative DUB assay

Qualitative Ub cleavage assays were performed as previously described (Keusekotten et al., 2013). For further details, see Appendix Supplementary Methods.

Protein crystallisation and structure determination

OTULINcatG281R crystals were grown by hanging drop vapour diffusion method and the structure solved by molecular replacement using PHASER (McCoy et al, 2007) with wild-type OTULINcat (PDB ID 3ZNV) as the search model. For further details, see Appendix Supplementary Methods.

Binding assays

Fluorescence anisotropy experiments were performed as previously described (Keusekotten et al., 2013). For further details, see Appendix Supplementary Methods.

Differential scanning fluorimetry (DSF) thermal unfolding experiments

Nano-DSF measurements were performed as previously described (Damgaard et al., 2016). For further details, see Appendix Supplementary Methods.

Cell culture

A primary fibroblast culture from patient III.2 was established from a skin punch biopsy. Primary fibroblasts were cultured in Ham’s F-10 nutrient mix + GlutaMAX™ (Life Technologies) supplemented with 20% iron-supplemented foetal calf serum (FCS) (#C8056, Sigma) (v/v) and penicillin/streptomycin (Life Technologies). Human THP-1 monocytes with stable short-hairpin RNA (shRNA)-mediated knock-down of OTULIN (shOTULIN) or a non-targeting control (shControl) were a kind gift from Dr. Mads Gyrd-Hansen (University of Oxford) (Hrdinka et al., 2016). THP-1 cells were cultured undifferentiated in RPMI-1640 + GlutaMAX™ (Life Technologies) supplemented with 1 mM sodium pyruvate (Life Technologies), 10% FCS (Life Technologies) (v/v), 50 μM β-mercaptoethanol and penicillin/streptomycin (Life Technologies). All cells were kept at 37°C in a humidified atmosphere at 5% CO₂. All cultures were found to be negative for mycoplasma contamination by regular PCR testing (Young et al., 2010).

Cell stimulations and signalling experiments

Primary fibroblasts or THP-1 cells were treated as indicated in figures and legends. For signalling experiments, cells were stimulated with recombinant human TNF (Life Technologies). For proteasomal inhibition, cells were treated with 10 μM MG132 (Sigma) in DMSO as indicated. For inhibition of autophagosomal degradation, cells were treated with 100 nM bafilomycin A1 from Streptomyces griseus (BafA) (Sigma) in DMSO as indicated. Cells were lysed either directly in sample buffer (50 mM Tris pH 6.8, 10% glycerol (v/v), 100 mM DTT, 2% SDS (w/v), bromophenol blue), sonicated using a microtip for 5 s at 30% amplitude on a Vibra-Cell VC750 (Sonics & Materials, Inc., Newton, CT) and boiled for 2 min, or lysed in RIPA buffer (50 mM Tris pH 7.4, 1% NP-40 (v/v), 0.5% deoxycholate (w/v), 0.1% SDS (w/v), 150 mM NaCl, 2 mM EDTA, 5 mM MgCl₂) for 20 min on ice, lysate cleared by centrifugation and supplemented with 4× sample buffer. For assessment of IκBα stability, THP-1 cells were washed in PBS and seeded in 96-well plates in complete medium ~16 h before they were treated with 50 μg/ml cycloheximide (CHX; Santa Cruz Biotechnology, Santa Cruz, CA) in DMSO as indicated. IκBα stability in primary fibroblasts was assayed by seeding the fibroblasts in 12-well plates 18–24 h prior to treatment with CHX as indicated. After CHX treatment, all cells were washed in PBS and lysed in RIPA buffer.

Immunoprecipitation of the TNF-RSC

Immunoprecipitation of the TNF receptor signalling complex (TNF-RSC) was performed using 100 ng/ml FLAG-tagged TNF (Enzo Life Sciences, Farmingdale, NY) as previously described (Fiiil et al., 2013). For further details, see Appendix Supplementary Methods.
Purification of endogenous polyUb conjugates by TUBE pull-down

Endogenous polyUb conjugates were purified from primary fibroblasts using TUBE affinity reagents as described previously (Damgaard et al., 2012; Fiil et al., 2013). For further details, see Appendix Supplementary Methods.

Ub chain composition analysis (AQUA-MS)

Details on LC-MS/MS methods for analysis of the cellular composition of Ub chain linkages can be found in Appendix Supplementary Methods.

Immunoblotting

Samples were resolved on 4–12% Bis-Tris NuPAGE gels (Life Technologies) and transferred to nitrocellulose or polyvinylidene fluoride (PVDF) membranes. Blots were visualised using Clarity Technologies) and transferred to nitrocellulose or polyvinylidene fluoride (PVDF) membranes. Blots were visualised using Clarity

Histology, immunohistochemistry and TUNEL assay

Biopsies were fixed in formalin and embedded in paraffin before sectioning and staining. Biopsies from patient III.2 were obtained with informed consent (see below) from the pathological archives at Hadassah Hebrew University Medical Center, Jerusalem, Israel. Healthy skin control biopsies were obtained from the Human Research Tissue Bank, Cambridge Biomedical Research Centre, Cambridge University Hospitals, UK. Deparaffinisation, haematoxylin and eosin (H&E) staining, cleaved caspase-3 immunohistochemical staining (anti-cleaved caspase-3, #9661, RRID AB_2341188, Cell Signaling Technology) with haematoxylin counterstaining, and TUNEL assays (TdT In Situ Apoptosis Detection kit, #4810-30-K, R&D Systems) with methyl green counterstaining were performed by NDBbio Laboratories, LLC., Baltimore, MD. Stained slides were scanned (20× objective), and image files (SVS files) were processed using the QuPath software (https://qupath.github.io/; Bankhead et al., 2017).

Statistics

Data are presented as mean ± standard error of the mean (SEM) or ± standard deviation (SD) as indicated. Sample number (n) indicates the number of independent biological samples in each experiment. Sample numbers and experimental repeats are indicated in figures and figure legends. Data were analysed using the two-way analysis of variance (ANOVA) with Sidak’s correction for multiple comparisons or the non-parametric Mann–Whitney U-test of the null hypothesis as indicated. For the two-way ANOVA tests, the Shapiro–Wilk test was used to assess normality of the data distributions. Generally, the datasets were normally distributed and as the variables analysed (cytokine secretion and cell viability) are generally accepted to be normally distributed, the use of the two-way ANOVA test was considered appropriate. Differences in means were considered statistically significant at P < 0.05. Analyses were performed using the GraphPad Prism software version 7.0b.

Study approval

Written informed consent was obtained from all subjects and family members. The study was approved by the ethical committees of Hadassah Medical Center and the Ministry of Health, Israel (Y.B.), and the South Birmingham Research Ethics Committee, UK (E.R.M.), and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

For additional methods and details, see Appendix Supplementary Methods.

Data availability

Due to restrictions from the patient consent approved by the research ethics committees, it is not be possible to deposit complete exome sequencing data in a public repository, but the data could be made available to interested researchers by contacting the corresponding author (Y.B.). Accession numbers, coordinates and structure factors for crystal structures of OTULINC2281R.
The paper explained

Problem
OTULIN is a deubiquitinae that removes methionine 1 (M1)-linked polyubiquitin chains conjugated by the linear ubiquitin chain assembly complex (LUBAC), and mutations OTULIN cause OTULIN-related autoimmune inflammatory syndrome (ORAS), a TNF-driven autoimmune inflammatory disease in humans. ORAS manifests clinically with a range of neonatal-onset inflammatory symptoms, including fever, skin inflammation (panniculitis), diarrhoea and arthritis. It was unclear which cells types are responsible for the development of these symptoms and how OTULIN deficiency affects M1-linked polyubiquitin signalling in cells to cause inflammation.

Results
We identified a new case of ORAS in which a Gly281 to Arg mutation in OTULIN causes the disease. To assess the cellular impact of loss of OTULIN in ORAS, we analysed the signalling response in patient-derived fibroblasts and in OTULIN-deficient human monocytes. This revealed that OTULIN loss in patient-derived fibroblasts leads to concomitant reduction of LUBAC and decreased TNF signalling, whereas OTULIN-deficient monocytes retain LUBAC expression and show increased signalling and TNF secretion. However, both cell types are sensitised to TNF-induced cell death. Remarkably, haematopoietic stem cell transplantation leads to complete resolution of all inflammatory symptoms associated with ORAS, showing that haematopoietic cells are necessary for development of ORAS inflammation. This indicates that ORAS pathogenesis involves hyper-inflammatory immune cells and TNF-induced death of both immune cells and non-haematopoietic cells.

Impact
OTULIN-related autoimmune inflammatory syndrome is a potentially fatal, neonatal-onset autoimmune inflammatory disease of unclear pathogenesis. Treatment with TNF inhibitors such as antibodies (e.g. infliximab) or TNF blockers (e.g. etanercept) effectively ameliorates inflammation, but there is currently no cure for ORAS. We show that haematopoietic cells are necessary for clinical manifestation of ORAS, suggesting that haematopoietic stem cell transplantation is a potentially curative treatment for ORAS.

have been deposited within the protein data bank with accession code 6I9C. Mass spectrometry data include global ubiquitin linkage analysis by AQUA and been deposited to the Mass Spectrometry Interactive Virtual Environment (MassIVE) (ftp://massive.ucsd.edu/MSV000083154) at University of California San Diego, CA.

Acknowledgements
We would like to thank Andrew N.J. McKenzie and members of the Komander laboratory for helpful discussions, Chris Johnson for help with biophysical experiments, France Monique Michele Docquier for support with culturing of primary cells, Mads Cyrd-Hansen and Mattia Zucca for sharing the THP-1 cell lines, Ruth Casey and Elizabeth Cromwell for help with healthy skin control biopsies and the staff at the Diamond Light Source (DLS) beam line I03 for their assistance. We would also like to thank the patients and their families for their contributions as well as all hospital staff at the Hadassah Hebrew University Medical Center; including Director, Professor Zeev Rotstein, for their commitment and support. Access to DLS was supported in part by the EU FP7 Infrastructure grant BIOSTRUCT-X [283570]. Work in the D.K. laboratory was supported by the Medical Research Council [U105192732], the European Research Council [724804], the Lister Institute for Preventive Medicine (to D.K.), a Marie-Skłodowska Curie Individual Fellowship from the European Commission [MC-IF-654019], a Lundbeckfonden Postdoctoral Fellowship [R232-2016-1904/R265-2017-2998] and a Research Fellowship from Corpus Christi College Cambridge (to R.B.D.). Work in the E.R.M. laboratory is supported by the NIHR (Senior Investigator Award and Cambridge NIHR Biomedical Research Centre), and the University of Cambridge has received salary support for E.R.M. from the NHS in the East of England through the Clinical Academic Reserve. The Human Research Tissue Bank is supported by the NIHR Cambridge Biomedical Research Centre. P.S. is supported by the Deutsche Forschungsgemeinschaft (Discovery and Evaluation of new Combined Immunodeficiency Disease Entities, DFG WA 1597/4–2) and the ERA-NET ERARE consortium (EURO-CID ERARE). Fig 3C was produced using Servier Medical Art (https://smart.servier.com/).

Author contributions
RBD, OE, DK and YB conceived the project and coordinated the research. RBD, PRE and KNS designed experiments. RBD performed and analysed all cell culture experiments, including the primary patient cells. PRE performed and analysed the biochemical and biophysical experiments. KNS performed and analysed the mass spectrometry experiments. RBD, PRE, KNS and DK interpreted the data. ERM provided experimental support and access to the Human Research Tissue Bank. YB, OE and PS were responsible for human clinical and genetic studies. RBD and DK wrote the paper with input from all authors.

Conflicts of interest
The authors declare that they have no conflict of interest.

For more information
https://www.omim.org/entry/617099

References
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7: 16878
Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M, Capriotti C, Cook M, Finger J, Hughes-Earle A et al (2014) Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol 192: 5476–5480
Boisson B, Laplantine E, Prando C, Giliani S, Israelisson E, Xu Z, Abhyankar A, Israel L, Trevejo-Nunez G, Bogunovic D et al (2012) Immunodeficiency, autoimmune inflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 13: 1178–1186
Boisson B, Laplantine E, Dobbs K, Cobat A, Tarantino N, Hazen M, Lidow HGW, Hopkins G, Du L, Belkadi A et al (2015) Human HOIP and LUBAC deficiency underlies autoimmune inflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. J Exp Med 212: 939–951
Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280–288
Damgaard RB, Nachbur U, Yabal M, Wong WW-L, Fiil B, Kastirr M, Rieser E, Rickard J, Cyrd-Hansen A, Peschel C et al (2012) The ubiquitin ligase XIAP recruits LUBAC for NOD2 signalling in inflammation and innate immunity. Mol Cell 46: 746–758
Damgaard RB, Fiil B, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, Jost P, Ehl S, Mailand N, Cyrd-Hansen M (2013) Disease-causing...
mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med 5: 1278 –1295
Damaagda RB, Walker JA, Marco-Casanova P, Morgan NV, Titheradge HL, Elliott PR, McHale D, Maher ER, McKenzie ANJ, Komander D (2016) The deubiquitinating OTULIN is an essential negative regulator of inflammation and autoimmunity. Cell 166: 1215 –1230.e20
Draper P, Kupka S, Reichert M, Draberova H, Lafont E, de Miguel D, Spilgies L, Surinova S, Taraborrelli L, Hartwig T et al (2015) LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Rep 13: 2258 –2272
Elliott PR, Nielsen SV, Marco-Casanova P, Fiil B, Keesekotten K, Mailand N, Freund SMV, Cyrd-Hansen M, Komander D (2014) Molecular basis and regulation of OTULIN-LUBAC interaction. Mol Cell 54: 335 –348
Elliott PR, Leske D, Hrdinka M, Bagola K, Fiil BK, McLaughlin SH, Wagstaff J, Volkmar N, Christianson JC, Kessler BM et al (2016) SPATA2 links CYLD to LUBAC, activates CYLD, and controls LUBAC signaling. Mol Cell 63: 990 –1005
Emmerich CH, Ordureau A, Strickson S, Arthur JSC, Pedrioli PGA, Komander D, Cohen P (2013) Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc Natl Acad Sci USA 110: 15247 –15252
Etzioni A, Ciechanover A, Pikarsky E (2017) Immune defects caused by mutations in the ubiquitin system. J Allergy Clin Immunol 139: 743 –753
Fiil B, Damaagda RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S, Mailand N, Choudhary C, Komander D, Cyrd-Hansen M (2013) OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell 50: 818 –830
Fuchs Y, Steller H (2015) Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat Rev Mol Cell Biol 16: 329 –344
Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, Webb AI, Rickard JA, Anderton H, Wong WW-L et al (2011) Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471: 591 –596
Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, Feltham R, Vince J, Warnken U, Wenger T et al (2009) Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 36: 831 –844
Harhaj EW, Dixit VM (2012) Regulation of NF-kB by deubiquitinases. Immunal Rev 246: 107 –124
Heger K, Wickliffe KE, Ndjoa A, Zhang J, Murthy A, Dugger DL, Malztman A, de Sousa Melo F, Hung J, Zeng Y et al (2018) OTULIN limits cell death and inflammation by deubiquitinating LUBAC. Nature 559: 120 –124
Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, England P, Rodriguez MS, Heger K, Wickliffe KE, Ndoja A, Zhang J, Murthy A, Dugger DL, Maltzman A, Hrdinka M, Cyrd-Hansen M, Komander D, Harhaj EW, Dixit VM (2016) The monogenic Purkinje cell heterotopia syndrome is caused by a frameshift mutation in the XIAP BIR2 domain. EMBO J 35: 4034 –4046
Hingx Wijk SJL, Goswami P, Nagy V, Terzic J, Manthiram K, Zhou Q, Aksentijevich I, Kastner DL (2011) Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep 10: 1250 –1258
HogenEsch H, Gijbels MJ, Offerman E, van Hooft J, van Bekkum DW, Zurcher C (1993) A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol 143: 972 –982
Hrdinka M, Fiil B, Zucca M, Leske D, Bagola K, Yabal M, Elliott PR, Damaagda RB, Komander D, Jost PJ et al (2016) CYLD limits Lys63- and Met1-linked ubiquitin at receptor complexes to regulate innate immune signaling. Cell Rep 14: 2846 –2858
Hrdinka M, Cyrd-Hansen M (2017) The Met1-linked ubiquitin machinery: emerging themes of (De)regulation. Mol Cell 68: 265 –280
Ikeda F, Deribe YL, Knäbäck HS, Stiegblitz B, Grabe C, Franz-Wachtel M, van Wijk SJL, Cosswami P, Nagy V, Terzic J et al (2011) SHARPN forms a linear ubiquitin ligase complex regulating NF-kB activity and apoptosis. Nature 471: 637 –641
Jiang X, Chen ZJ (2012) The role of ubiquitination in immune defence and pathogen evasion. Nat Rev Immunol 12: 35 –48
Kalilias GD, Ivashkov LB (2016) TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 12: 49 –62
Keusekotten K, Elliott PR, Glocker L, Fiil B, Damaagda RB, Kaluthu Y, Wauer T, Hospenthal MK, Cyrd-Hansen M, Krappmann D et al (2013) OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 153: 1312 –1326
Kirsiko T, Kamei K, Murata S, Kato M, Fukumoto H, Kanie M, Sano S, Tokunaga F, Tanaka K, Iwai K (2008) A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 25: 4877 –4887
Kirkpatrick DS, Hathaway NA, Hanna J, Elsasser S, Rush J, Finley D, King RW, Cygi SP (2006) Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex class chain topology. Nat Cell Biol 8: 700 –710
Komander D, Rape M (2012) The ubiquitin code. Annu Rev Biochem 81: 203 –229
Kumari S, Redouane Y, López-Mosqueda J, Shiraishi R, Romanowska M, Lutzmayer S, Kuiper J, Martinez C, Dikic I, Pasparakis M et al (2014) Sharpin prevents skin inflammation by inhibiting TNFRI-induced keratinocyte apoptosis. Elife 3: e03442
Kupka S, de Miguel D, Draber P, Martino L, Surinova S, Rittinger K, Walczak H (2016a) SPATA2-mediated binding of CYLD to HOIP enables CYLD recruitment to signaling complexes. Cell Rep 16: 2271 –2280
Kupka S, Reichert M, Draber P, Walczak H (2016b) Formation and removal of poly-ubiquitin chains in the regulation of tumor necrosis factor-induced gene activation and cell death. FEBS J 283: 2626 –2639
Manthiram K, Zhou Q, Aksentijevich I, Kastner DL (2017) The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol 18: 832 –842
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658 –674
Nathan C, Ding A (2010) Nonresolving inflammation. Cell 140: 871 –882
Nilsson J, Schoser B, Lafoer P, Kalev O, Lindberg C, Romero NB, Dávila López A, Makman HO, Wahbi K, Igleseder S et al (2013) Polysaccharide body myopathy caused by defective ubiquitin ligase RBCK1. Ann Neural 74: 914 –919
Pasparakis M (2009) Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 9: 778 –788
Peltzer N, Rieser E, Taraborrelli L, Draber P, Darding M, Pernaute B, Shimizu Y, Sarr A, Draberova H, Montinaro A et al (2014) HOIP deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death. Cell Rep 9: 153 –165
Peltzer N, Darding M, Montinaro A, Draber P, Draberova H, Kupka S, Rieser E, Fisher A, Hutchinson C, Taraborrelli L et al (2018) LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. Nature 557: 112 –117
Rickard JA, Anderton H, Etemadi N, Nachbur U, Darding M, Peltzer N, Lalauoi N, Lawlor KE, Vanyai H, Hall C et al (2014) TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. Elife 3: e03464
Rivkin E, Almeida SM, Cecчерrelli DF, Juang Y-C, MacLean TA, Srikumar T, Huang H, Dunham WH, Fukumura R, Xie G et al (2013) The linear ubiquitin-specific deubiquitinase guvbeta regulates angiogenesis. Nature 498: 318 –324
Schaever V, Akutsu M, Olma MH, Gomes LC, Kawasaki M, Dikic I (2014) Binding of OTULIN to the PUB domain of HOIP controls NF-kB signaling. Mol Cell 54: 349 –361

EMBO Molecular Medicine
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B et al (2012) Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9: 676–682

Seymour RE, Hasham MG, Cox GA, Shultz LD, HogenEsch H, Roopenian DC, Sundberg JP (2007) Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. *Genes Immun* 8: 416–421

Stieglitz B, Rana RR, Koliopoulos MG, Morris-Davies AC, Schaeffer V, Christodoulou E, Howell S, Brown NR, Dikic I, Rittinger K (2013) Structural basis for ligase-specific conjugation of linear ubiquitin chains by HOIP. *Nature* 503: 422–426

Swatek KN, Komander D (2016) Ubiquitin modifications. Cell Res 26: 399–422

Takuchi T, Nakagawa T, Tamiya H, Fujita H, Sasaki Y, Saeki Y, Takeda H, Sawasaki T, Buchberger A, Kimura T et al (2014) Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN. *Genes Cells* 19: 254–272

Tang Y, Joo D, Liu G, Tu H, You J, Jin J, Zhao X, Hung M-C, Lin X (2018) Linear ubiquitination of cFLIP induced by LUBAC contributes to TNFα-induced apoptosis. *J Biol Chem* 293: 20062–20072

Taraborrelli L, Peltzer N, Montinaro A, Kupka S, Rieser E, Hartwig T, Sarr A, Darding M, Draber P, Haas TL et al (2018) LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L. *Nat Commun* 9: 3910

Tokunaga F, Sakata S-I, Saeki Y, Satomi Y, Kirisako T, Kamei K, Nakagawa T, Kato M, Murata S, Yamaoka S et al (2009) Involvement of linear polyubiquitylation of NEMO in NF-κB activation. *Nat Cell Biol* 11: 123–132

Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S-I, Tanaka K, Nakano H, Iwai K (2011) SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. *Nature* 471: 633–636

Wang K, Kim C, Bradfield J, Guo Y, Toskala E, Otieno FG, Hou C, Thomas K, Cardinale C, Lyon G et al (2013) Whole-genome DNA/RNA sequencing identifies truncating mutations in RBCK1 in a novel Mendelian disease with neuromuscular and cardiac involvement. *Genome Med* 5: 67

WHO Multicentre Growth Reference Study Group (2006) WHO Child Growth Standards based on length/height, weight and age (www.who.int/childgrowth/standards/en). *Acta Paediatr Suppl* 450: 76–85

van Wijk SJL, Fricke F, Herhaus L, Gupta J, Hötte K, Pampaloni F, Grumati P, Kaulich M, Sou Y-S, Komatsu M et al (2017) Linear ubiquitination of cytosolic Salmonella Typhimurium activates NF-κB and restricts bacterial proliferation. *Nat Microbiol* 2: 17066

Young L, Sung J, Stacey G, Masters JR (2010) Detection of Mycoplasma in cell cultures. *Nat Protoc* 5: 929–934

Zhou Q, Yu X, Demirkaya E, Deitich N, Stone D, Tsai WL, Kuehn HS, Wang H, Yang D, Park YH et al (2016) Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. *Proc Natl Acad Sci USA* 113: 10127–10132

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.